

Crowe RCA Benchmarking Analysis

Transparent Doesn't Equal Rational: Problems With Transparency Order

January 2020



President Donald Trump's recent executive order on price transparency touched a nerve for many healthcare consumers who seek practical information for purchasing decisions about "shoppable" medical care (that is, services offered by multiple providers for which consumers can compare prices and quality). Although the order addresses convincing – but not surprising – disparities in price across like services, it does not portray what the shopping process might need to look like for consumers, nor does it explain what information they might encounter to make the best decisions for their health.

**This is a long way from the
online shopping experience.**

To further study this topic, Crowe utilized its proprietary Crowe Revenue Cycle Analytics (RCA) solution, which captures every patient transaction for more than 1,200 hospitals nationally for purposes of automating hindsight, accounts receivable valuation, and net revenue analyses. Within its benchmarking database, Crowe analyzed a portfolio including 45 states and comprising 707 hospitals within Medicaid-expansion states and 445 hospitals in nonexpansion states, as of 2019. Crowe combines financial transaction information with 835/837 account-level data to produce

comparative metrics. These metrics include accounts receivable, denials, bad debt, credit balance, and cash to expected pay.

Crowe analyzed its national hospital database of 100 common outpatient procedures priced at more than \$500 in gross charges (the list price that hospitals post in their system), assuming that more shopping around would occur on higher-dollar items. Crowe also reviewed the average allowable revenue (the amount actually paid) for each of the outpatient procedures studied.

Exhibit 1: Disparity in gross charges and amounts paid for high-cost procedures

Top 100 outpatient procedures (> \$500 in gross charges)



% difference between highest and lowest **gross charge** for each procedure



% difference between highest and lowest **allowed amount** for each procedure

Source: Crowe analysis

Overall, the national disparity between gross charges for each procedure was significant, exhibiting on average a 297% difference between lowest and highest gross charge for each individual procedure (Exhibit 1). The national disparity between allowable revenue (the expected payment) for each procedure also was notable at 236%. It is not uncommon for some disparity nationally, as numbers represent different labor markets and – to some degree – different economic and managed care negotiation circumstances. That said, an example of this disparity is Current Procedural Terminology (CPT) code 99285 (high-severity, potentially life-threatening, emergency room visit) in which the highest (top 5% of hospitals) gross charge was \$3,499 and the lowest (bottom 5% of hospitals) gross charge was \$692, representing a 406% difference. This differential also holds true for the allowed amounts, in which the highest (top 5% of hospitals) exhibited a payment


expectation of \$736, whereas the lowest (bottom 5% of hospitals) exhibited a payment expectation of only \$192.

This trend is also evident on a local basis. For example, Crowe reviewed a standard magnetic resonance imaging (MRI) procedure within a metropolitan area of more than 3 million people and noted the following, as shown in Exhibit 2:

- 115% difference between the highest (top 5% of hospitals) average gross charge (\$4,548) and the lowest (bottom 5% of hospitals) gross charge (\$2,115), with the median at \$3,105
- 126% difference between the highest (top 5% of hospitals) allowed amount (\$1,390) and the lowest (bottom 5% of hospitals) allowed amount (\$615), with the median at \$917

This differential shows that two patients could undergo the exact same MRI procedure, with one paying \$1,390 and the other paying \$615.

Exhibit 2: Disparity in knee MRI charges and amounts paid, metropolitan area > 3 million people



Source: Crowe analysis



Transparent Doesn't Equal Rational: Problems With Transparency Order

In the future, patients might be able to actively shop for and select a medical service (such as a knee MRI) based on a transparent pricing tool. But it should be noted that a process based on price does not take into account the many other factors that a consumer typically might consider during the normative purchasing process.

That is, to place common procedures into a commodities category based purely on price means that the consumer selection process does not consider other determinants such as:

- **Brand value perception.** Whom do I trust?
- **Consumer ratings.** What have other patients experienced?
- **Quality of care.** How do I know the provider is good?
- **Convenience and accessibility.** Where is the provider located?
- **Customer experience.** How well does the provider treat me?

And most important:

- **Urgency.** Do I have time to comparison shop? In the previous example of the price disparity of CPT code 99285, it is doubtful that a patient will shop for the lowest price in that circumstance.

Overall, U.S. consumers have grown accustomed to convenient online shopping, which allows them to easily and quickly comparison shop.





Somewhere beneath the political and policy debates about economic drivers of transparent pricing is the true, hidden desire of most patients or consumers – rational pricing. Consumers want to understand the confusing disparity among prices for similar services. As such, an increase in transparency, which creates a lower standard deviation on pricing between hospitals for similar services, will allow consumers to apply their normative, rational purchasing criteria. Hospitals that can clearly state the total price to be paid for a set of clinical services – before those services are delivered – and then charge only that price after the services are delivered will give consumers basic information they need to make rational decisions.



Learn more

For more information on the Crowe RCA benchmarking program, please visit crowe.com/benchmarking or contact:

Ken Ruiz
Principal
+1 317 706 2765
ken.ruiz@crowe.com

crowe.com/benchmarking

The Crowe Revenue Cycle Analytics (Crowe RCA) solution was invented by Derek Bang of Crowe LLP. The Crowe RCA solution is covered by U.S. Patent number 8,301,519.

"Crowe" is the brand name under which the member firms of Crowe Global operate and provide professional services, and those firms together form the Crowe Global network of independent audit, tax, and consulting firms. "Crowe" may be used to refer to individual firms, to several such firms, or to all firms within the Crowe Global network. The Crowe Horwath Global Risk Consulting entities, Crowe Healthcare Risk Consulting LLC, and our affiliate in Grand Cayman are subsidiaries of Crowe LLP. Crowe LLP is an Indiana limited liability partnership and the U.S. member firm of Crowe Global. Services to clients are provided by the individual member firms of Crowe Global, but Crowe Global itself is a Swiss entity that does not provide services to clients. Each member firm is a separate legal entity responsible only for its own acts and omissions and not those of any other Crowe Global network firm or other party. Visit www.crowe.com/disclosure for more information about Crowe LLP, its subsidiaries, and Crowe Global.

The information in this document is not – and is not intended to be – audit, tax, accounting, advisory, risk, performance, consulting, business, financial, investment, legal, or other professional advice. Some firm services may not be available to attest clients. The information is general in nature, based on existing authorities, and is subject to change. The information is not a substitute for professional advice or services, and you should consult a qualified professional adviser before taking any action based on the information. Crowe is not responsible for any loss incurred by any person who relies on the information discussed in this document.
© 2020 Crowe LLP.